Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
CH0461929603
Mon, 23.12.2024
Xlife Sciences AG
Zurich, 23rd of December 2024: Xlife Sciences AG (SIX: XLS) is pleased to announce that its portfolio company, FUSE-AI GmbH, is engaged in discussions regarding a potential acquisition by Pineapple Power Corporation PLC, a UK-based company listed on the London Stock Exchange. The proposed transaction would represent a significant milestone in FUSE- [ … ]
Thu, 19.12.2024
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): ESG
Xlife Sciences AG Publishes 2023 ESG Report: A Continued Commitment to Sustainable Innovation
19.12.2024 / 07:00 CET/CEST
Zurich, 19th of December 2024: Xlife Sciences AG (SIX: XLS) today announced the release of its 2023 ESG Report, marking another milestone in the company’s journey [ … ]
Mon, 16.12.2024
Xlife Sciences AG
Zurich, 16th of December 2024: Xlife Sciences AG (SIX: XLS) announces the planned listing of its portfolio company, VERAXA Biotech AG, on the NASDAQ Stock Market, New York, USA, following the unanimous resolution passed at the Regular Board Meeting on December 13, 2024. The listing is scheduled for fiscal year of 2025 and will be executed in collab [ … ]
Mon, 30.09.2024
Xlife Sciences AG
Zurich, 30th of September 2024: The management of Xlife Sciences AG (SIX:XLS) was commissioned on September 3, 2024, after an intensive review of all available options and offers from the Board of Directors, to implement a strategy to increase market capitalization and, consequently, the stock price, as well as the liquidity and tradability of the [ … ]
Thu, 19.09.2024
Xlife Sciences AG
Zurich, 19th of September 2024: Xlife Sciences AG (SIX: XLS) today published its 2024 Half-Year Report and announced significant progress in its business development. Despite a challenging market environment, the company was able to further expand its innovative strength and advance new partnerships and developments within its diversified portfolio [ … ]
Thu, 19.09.2024
Xlife Sciences AG
Zurich, 19th of September 2024: Xlife Sciences AG (SIX: XLS) today published its 2024 Half-Year Report and announced significant progress in its business development. Despite a challenging market environment, the company was able to further expand its innovative strength and advance new partnerships and developments within its diversified portfolio [ … ]
Tue, 03.09.2024
Xlife Sciences AG
Zurich, 3rd of September 2024: Xlife Sciences AG (SIX: XLS) today announced that the Board of Directors has completed the strategic review and, as of September 2, 2024, has tasked management with implementing the process. The shareholders will be informed of the next steps by September 30, 2024, at the latest.
The size and diversity of the portfoli [ … ]
Fri, 28.06.2024
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): AGMEGM
Xlife Sciences AG: Successful General Assembly and New Trading Hours on the Sparks Segment of SIX
28.06.2024 / 18:00 CET/CEST
Zurich, 28th of June 2024: Xlife Sciences AG (SIX: XLS), a leading company in the development and commercialization of technologies and therapies in the li [ … ]
Fri, 28.06.2024
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): AGMEGM
Xlife Sciences AG: Successful General Assembly and New Trading Hours on the Sparks Segment of SIX
28.06.2024 / 18:00 CET/CEST
Zurich, 28th of June 2024: Xlife Sciences AG (SIX: XLS), a leading company in the development and commercialization of technologies and therapies in the li [ … ]
Wed, 26.06.2024
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): Market launch/Product Launch
Xlife Sciences AG Reports Success in Liver Diagnostics – x-nuclear diagnostics GmbH Achieves Market Readiness
26.06.2024 / 07:00 CET/CEST
Zurich, 26th of June 2024: Xlife Sciences AG announces significant progress in the development and application of innovat [ … ]